Literature DB >> 1829991

Detection of circulating Fc epsilon R2/CD23+ monocytes in patients with rheumatic diseases.

H Becker1, P Potyka, C Weber, K Federlin.   

Abstract

Recently, in vitro studies have demonstrated that expression of Fc epsilon R2/CD23 on normal monocytes can be specifically induced by IL-4. In order to investigate the interaction of IL-4 and monocytes in rheumatic diseases, flow cytometry studies were performed. Elevated numbers of circulating Fc epsilon R2/CD23+ monocytes were detected in patients with progressive systemic sclerosis (PSS) as compared with controls. In addition, supernatants derived from phytohaemagglutinin-stimulated peripheral blood mononuclear cells of PSS patients contained high activity to induce Fc epsilon R2/CD23 on CD14+ monocytes. An increased frequency of Fc epsilon R2/CD23+ monocytes was also observed in rheumatoid arthritis, and sequential studies in patients with systemic lupus erythematosus showed a close relationship between Fc epsilon R2/CD23+ monocytes and disease activity. It is suggested that IL-4 has an important role in the pathogenesis of PSS by activating monocytes, and might also contribute to monocyte activation in other rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829991      PMCID: PMC1535706          DOI: 10.1111/j.1365-2249.1991.tb05682.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

Review 1.  Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system?

Authors:  J Westermann; R Pabst
Journal:  Immunol Today       Date:  1990-11

2.  Ultrastructure of cutaneous cellular infiltrates in scleroderma.

Authors:  R Fleischmajer; J S Perlish; W P West
Journal:  Arch Dermatol       Date:  1977-12

3.  A B cell-specific differentiation antigen, CD23, is a receptor for IgE (Fc epsilon R) on lymphocytes.

Authors:  K Yukawa; H Kikutani; H Owaki; K Yamasaki; A Yokota; H Nakamura; E L Barsumian; R R Hardy; M Suemura; T Kishimoto
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

4.  IgE receptors on human lymphocytes. II. Detection of cells bearing IgE receptors in unstimulated mononuclear cells by means of a monoclonal antibody.

Authors:  G Delespesse; M Sarfati; M Rubio-Trujillo; T Wolowiec
Journal:  Eur J Immunol       Date:  1986-07       Impact factor: 5.532

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens.

Authors:  R M Crawford; D S Finbloom; J Ohara; W E Paul; M S Meltzer
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation.

Authors:  G Janossy; G Panayi; O Duke; M Bofill; L W Poulter; G Goldstein
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

9.  Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus.

Authors:  J Alcocer-Varela; A Laffon; D Alarcón-Segovia
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

10.  Human recombinant interleukin 4 induces Fc epsilon R2/CD23 on normal human monocytes.

Authors:  D Vercelli; H H Jabara; B W Lee; N Woodland; R S Geha; D Y Leung
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  7 in total

1.  Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease.

Authors:  H Becker; A Langrock; K Federlin
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Elevated soluble CD23 levels in the sera from patients with localized scleroderma.

Authors:  S Sato; M Fujimoto; K Kikuchi; H Ihn; K Tamaki; K Takehara
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

3.  Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).

Authors:  C Ribbens; V Bonnet; M J Kaiser; B Andre; O Kaye; N Franchimont; D de Groote; Y Beguin; M G Malaise
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

4.  IL-10 suppresses cell surface CD23/Fc epsilon RII expression, not by enhancing soluble CD23 release, but by reducing CD23 mRNA expression in human monocytes.

Authors:  A Morinobu; S Kumagai; H Yanagida; H Ota; H Ishida; M Matsui; J Yodoi; K Nakao
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

5.  Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients.

Authors:  A Haddad; J Bienvenu; P Miossec
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

6.  Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus.

Authors:  W A Nockher; R Wigand; W Schoeppe; J E Scherberich
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

7.  Molecular blocking of CD23 supports its role in the pathogenesis of arthritis.

Authors:  Jérôme Rambert; Maria Mamani-Matsuda; Daniel Moynet; Pierre Dubus; Vanessa Desplat; Tina Kauss; Joël Dehais; Thierry Schaeverbeke; Khaled Ezzedine; Denis Malvy; Philippe Vincendeau; M Djavad Mossalayi
Journal:  PLoS One       Date:  2009-03-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.